TBC1 domain family member 23Genealiases: NS4ATP1 · PCH11
Q-omics provides the consensus-scored TBC1D23 profile across patient tissues and cancer cell-line models. TBC1D23 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D23 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TBC1D23 RNA expression shows 20,323 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where TBC1D23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D23 survival associations across molecular data types. TBC1D23 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D23 RNA expression–survival associations across cancer types. High TBC1D23 expression shows unfavorable associations in PAAD, LGG and UCEC, but favorable associations in KIRC, UCS and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D23 RNA expression.
This table summarizes TBC1D23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D23 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, CHOL and LUSC. The HNSC box plot shows higher TBC1D23 RNA expression in tumor versus normal tissue (log2 FC = +0.713, t-test p < 0.001).
This table shows molecular features associated with TBC1D23 in patient tissues and cancer cell lines. In patient samples, TBC1D23 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
